Longevity & AgingPress Release

FDA adds NAION eye warning to GLP-1 drugs, leaving patients and doctors in a bind

The FDA now requires NAION vision-loss warnings on all GLP-1 drugs. An ophthalmologist argues the key question, whether to stop after diagnosis, is unstudied.

Thursday, November 19, 2026 1 view
Published in MedPage Today
Article visualization: FDA adds NAION eye warning to GLP-1 drugs, leaving patients and doctors in a bind

Summary

The FDA announced on November 9 that all GLP-1 drugs, including semaglutide and tirzepatide, must carry new warnings about a possible increased risk of NAION, a rare form of sudden, painless vision loss caused by reduced blood flow to the optic nerve. This opinion piece, by ophthalmologist Henry Bair, argues the warning is welcome but incomplete. Across 126 clinical trials, the FDA found 15 probable cases: about six per 100,000 patient-years on GLP-1 drugs versus four on placebo or other diabetes drugs. Observational studies also raise concern, but they cannot fully separate drug effects from the underlying conditions. No one knows whether continuing a GLP-1 after NAION raises risk in the other eye, or whether stopping lowers it. Bair urges the FDA to study outcomes after stopping, continuing or switching. Until then, he recommends that patient, eye doctor and prescriber weigh the decision together.

0:00--:--

Detailed Summary

GLP-1 drugs are among the most widely used medications in the United States. A March 2026 KFF poll found about one in eight adults currently taking one and one in five having ever taken one. That scale means even a rare side effect touches many people, which is why a new FDA safety action matters.

On November 9, the FDA required new warnings across the whole GLP-1 class, including semaglutide and tirzepatide, about a possible increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). The condition occurs when inadequate blood flow damages the optic nerve. It causes sudden, painless vision loss, often noticed on waking, can be permanent, and has no proven reversing treatment.

The evidence is mixed in size and quality. Across 126 clinical trials, the FDA identified 15 probable NAION cases, roughly six per 100,000 patient-years with GLP-1 drugs versus four with placebo or other diabetes drugs. Larger observational studies raised concern, but their estimates vary and cannot fully untangle drug effects from the conditions that led to treatment. The mechanism is unknown. One hypothesis is that rapid blood sugar reduction causes swelling where the optic nerve enters the eye, compromising blood flow in susceptible people.

The author's central point concerns patients who already have NAION. Having it in one eye raises the risk in the other, yet no data show whether staying on the drug adds risk or stopping reduces it. Stopping has costs: some patients have diabetes resistant to other treatments, and certain GLP-1 drugs reduce heart attack or kidney disease risk. European guidance says to stop semaglutide if NAION is confirmed, while the FDA advises considering discontinuation unless benefits clearly outweigh risk. Bair recommends involving the prescriber before any change.

Caveats: this is an opinion piece, not new research. The absolute risk appears small, the causal link is not established, and one major FDA study excluded people with prior optic nerve damage, so it cannot answer the post-diagnosis question.

Key Findings

  • FDA now requires NAION warnings on all GLP-1 drugs, including semaglutide and tirzepatide, announced November 9.
  • In 126 trials, 15 probable NAION cases: about six per 100,000 patient-years on GLP-1s versus four on placebo or other diabetes drugs.
  • Observational studies raise concern but cannot fully separate drug effects from underlying disease; causation is not established.
  • No data show whether stopping, continuing or switching a GLP-1 after NAION changes risk in the other eye.
  • European guidance says stop semaglutide if NAION is confirmed; FDA says consider stopping unless benefits clearly outweigh risk.

Methodology

This is an opinion piece (Second Opinions) in MedPage Today by an ophthalmologist, summarizing FDA trial-level data and observational studies rather than presenting new research. The trial figures are small-count, based on 15 probable cases, and the observational data carry confounding. The mechanism hypothesis (rapid glucose drop causing optic disc swelling) is speculative.

Study Limitations

The article is truncated and is an opinion, so verify figures against the FDA safety communication and the underlying studies. Causality, mechanism and outcomes after stopping or continuing remain unestablished. Risk estimates differ across observational studies and by patient population.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: